Faron Pharmaceuticals

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Our mission is to develop novel treatments to improve the lives of patients with unmet medical needs.

Our vision is to become a world-leading biopharmaceutical company delivering life-saving treatments to patients with unmet medical needs.

Faron Pharmaceuticals has received numerous awards, including the European Biopharmaceutical Award in 2008, the Finnish BioPharma Excellence Award in 2010, and the ‘Innovation of the Year’ award from the Finnish association for pharmaceutical industry in 2013.